Artemisinin Combination Therapy Market Companies
Novartis AG, KPC Pharmaceuticals, Inc., Bliss GVS, Cipla, and other companies are major participants in the artemisinin combination therapy market. The Artemisinin Combination Therapy (ACT) company is focusing on developing more effective and affordable formulations, such as drug-resistant and kid-safe variants, in order to enhance treatment outcomes and accessibility. Working with governments and international health organizations is another important strategy to expand distribution in malaria-endemic areas. To ensure consistent availability, local production and supply linkages are also reinforced. These programs support global efforts to eradicate malaria, combat drug resistance, and improve patient compliance.
List of Key Players in the Market:
- Novartis AG
- KPC Pharmaceuticals, Inc
- Shanghai Fosun Pharmaceutical?Group?Co., Ltd.
- AJANTA PHARMA LTD.
- Cipla
- Ipca Laboratories Ltd.
- NEM Laboratories
- Bliss GVS
- SHINPOONG.CO,.LTD
- Dr. Reddy’s Laboratories Ltd
- Manus Bio Inc.
- AdvaCare Pharma
Recent News:
- Novartis declared on May 2021 that since 1999, it has provided one billion antimalarial therapy sessions. Malaria-endemic nations worldwide received about 90% of this artemisinin-based combination therapy (ACT) for no profit.
- The Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project was initiated by a meeting of researchers in Bangkok, on January 2019. DeTACT is a large, 14-site trial funded by UKaid and the UK Department for International Development (DfID) and led by MORU. It will examine the safety, tolerability, and effectiveness of two Triple Artemisinin Combination Therapy (TACT) combinations using combinations of currently available antimalarial medications in eight African and five Asian countries.